Crit Care:血小板与淋巴细胞比值对急性肾损伤患者预后的预测价值如何?

2017-10-21 xing.T MedSci原创

在AKI患者中,术前PLR与生存率之间存在U形相关。PLR似乎是患有AKI危重病患者一个新的独立预后指标。

炎症在急性肾损伤(AKI)的发生和发展中起着重要的作用。然而,关于血小板与淋巴细胞比率(PLR),一种全身性炎症标志物,在AKI患者中预后效应的证据较少。近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,在这项研究中,研究人员调查了PLR在患有AKI的危重患者预后预测中的价值。

研究人员从重症监护病房数据库中提取病人数据,采用光滑曲线拟合来测定PLR的临界值,并对这些患者进行分组。其临床结果为ICU内30天和90天的死亡率。研究人员使用Cox比例风险模型来评估PLR和患者生存之间的相关性。

该研究共纳入10859例发AKI的ICU患者。在30天和90天共有2277例和3112例患者死亡。PLR和90天和30天死亡率之间均呈U型关系,最低的风险值变化范围从90到311。考虑到风险值 < 90和 > 311,90天死亡率调整后的风险比(95%可信区间)分别为1.25(1.12-1.39)和1.19(1.08-1.31)。30天死亡率也可以观察到类似的趋势。PLR和年龄以及心率之间的相互作用也发现具有统计学意义。只有当PLR<90时,年轻(年龄<65岁)和心率较快(≥89.4次/分)的患者往往有较差的预后,而只有当PLR>311时,老年(年龄≥65岁)与心率较慢(<89.4次/分)具有较高的风险(对于年龄P<0.001;对于心率P<0.001)。

由此可见,在AKI患者中,术前PLR与生存率之间存在U形相关。PLR似乎是患有AKI危重病患者一个新的独立预后指标。

原始出处:

Chen-Fei Zheng,,et al. Prognostic value of platelet-to-lymphocyte ratios among critically ill patients with acute kidney injury.Critical Care.2017. https://doi.org/10.1186/s13054-017-1821-z

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1691933, encodeId=523f169193360, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Aug 15 15:49:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302101, encodeId=b15d13021019a, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397346, encodeId=060e139e346cb, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626471, encodeId=c08116264e149, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254856, encodeId=db4d2548562f, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Oct 21 11:07:20 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1691933, encodeId=523f169193360, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Aug 15 15:49:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302101, encodeId=b15d13021019a, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397346, encodeId=060e139e346cb, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626471, encodeId=c08116264e149, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254856, encodeId=db4d2548562f, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Oct 21 11:07:20 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1691933, encodeId=523f169193360, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Aug 15 15:49:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302101, encodeId=b15d13021019a, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397346, encodeId=060e139e346cb, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626471, encodeId=c08116264e149, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254856, encodeId=db4d2548562f, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Oct 21 11:07:20 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1691933, encodeId=523f169193360, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Aug 15 15:49:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302101, encodeId=b15d13021019a, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397346, encodeId=060e139e346cb, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626471, encodeId=c08116264e149, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254856, encodeId=db4d2548562f, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Oct 21 11:07:20 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1691933, encodeId=523f169193360, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Aug 15 15:49:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302101, encodeId=b15d13021019a, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397346, encodeId=060e139e346cb, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626471, encodeId=c08116264e149, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Mon Oct 23 00:49:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254856, encodeId=db4d2548562f, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Oct 21 11:07:20 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
    2017-10-21 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

相关资讯

Minerva Anestesiol:从分子层面探讨脓毒症引起的急性肾损伤

在重症病房里,40%-50%的脓毒症患者都会发生急性肾脏损伤,但脓毒症患者与急性肾损伤(AKI)之间的分子差异仍知之甚少。在这里,我们研究了脓毒症患者基因表达的变化,结合传统的肾脏生理参数,找出不同基因对AKI发生的影响。

Diabetes Care:SGLT2抑制剂服用者发生急性肾损伤的风险分析!

由此可见,该研究结果并未表明AKI风险增加与T2D患者服用SGLT2抑制剂有关。

Shock:内皮细胞损伤预示重症患者急性肾损伤较难恢复

重症患者发生急性肾损伤(AKI)在病理生理和预后方面均存在异质性,然而内皮细胞损伤在难治性AKI发病机制中的作用尚未阐明。本研究目的为确定内皮细胞损伤的生物标志物是否独立于肾脏的炎性损伤,从而预测急性肾损伤的预后。

Crit Care:循环可溶性Fas水平(sCD95)与非恢复型AKI的发生风险相关!

由此可见,识别FAS介导的通路中可改变的靶点可能有助于临床上重要的AKI的预防和治疗策略。

J Am Heart Assoc:急诊血管成形术后AKI 造影剂是罪魁祸首?

与接受择期干预的患者相比,接受急诊经皮冠状动脉介入治疗(pPCI)的患者被认为具有造影剂(CM)诱导的急性肾损伤(CI-AKI)的较高风险,但pPCI后肾功能的恶化也可能是由于多种其他因素导致。2017年6月,发表在《J Am Heart Assoc.》的一项研究调查了造影剂暴露和pPCI后AKI发生率之间的因果关系。请看本期多学科讨论组临床药师各抒己见为您梳理本文看点—— 背景:pPCI后急性

JACC:慢性肾病与经导管主动脉瓣置换住院结局的关系

CKD或ESRD患者TAVR后的住院结局差。